PDCD1 and melanoma: Even though MRX34 administration achieved partial response in isolated cases previously heavily treated with resection and PD-1 inhibitor, the clinical phase 1 trial of MRX34 for melanoma was terminated due to the development of serious irAEs such as seizure and disobedient mentality [131,132].